Dispensary Files for Summary Judgment Against Jushi on Antitrust Claims

Motion Targets Alleged Market Manipulation

The plaintiff dispensary argues that Jushi's conduct meets the legal threshold for summary judgment, meaning no material facts remain in dispute. Court filings show the retailer claims Jushi used its position as a vertically integrated MSO to exclude competitors from wholesale supply channels and retail markets in Pennsylvania.

The motion zeroes in on Jushi's alleged refusal to supply wholesale cannabis products to independent retailers while simultaneously expanding its own retail footprint. Pennsylvania operates under a limited-license regime that caps the number of dispensary permits. The plaintiff characterizes this as a "bottleneck market" vulnerable to anticompetitive behavior.

Sherman Act Claims at Center of Dispute

The lawsuit invokes Section 2 of the Sherman Antitrust Act, which prohibits monopolization and attempted monopolization of interstate commerce. Cannabis remains federally illegal under the Controlled Substances Act, but federal courts have increasingly entertained antitrust claims in state-legal cannabis markets, treating the economic activity as cognizable under federal competition law.

The plaintiff's summary judgment motion argues that Jushi's vertical integration—owning both cultivation facilities and retail dispensaries—created an inherent conflict of interest that harmed competition. It's a structural problem, the retailer contends. The motion seeks both injunctive relief to compel wholesale access and monetary damages for lost revenue.

Jushi's Defense Strategy Remains Opaque

Jushi Holdings hasn't publicly responded to the summary judgment motion. Its defense arguments remain under seal pending court review. The Pennsylvania-based MSO operates more than 30 dispensaries across seven states and reported $518 million in revenue for fiscal year 2025.

Legal observers note that Jushi will likely argue that its refusal to supply competitors falls within legitimate business judgment, particularly given the capital-intensive nature of cannabis cultivation and the regulatory constraints on interstate commerce.

Pennsylvania's Regulatory Framework Under Scrutiny

Pennsylvania's medical cannabis program, launched in 2018, issues a fixed number of grower-processor and dispensary permits through a competitive application process. The state doesn't mandate vertical separation. Companies like Jushi can control both cultivation and retail operations—a structure that mirrors markets in Illinois and Massachusetts but contrasts sharply with California's open-market model.

Critics of Pennsylvania's system argue the limited-license structure inherently favors large MSOs and creates barriers to entry for independent operators. The state's Department of Health has issued 50 grower-processor permits and 150 dispensary permits since program inception. No new licenses since 2023.

Antitrust Litigation Accelerates Across U.S. Cannabis Markets

The Jushi case is part of a broader wave of antitrust litigation in state-legal cannabis markets, particularly in jurisdictions with capped licensing regimes. Similar lawsuits have been filed in Illinois, Ohio, and Maryland, where independent retailers allege that vertically integrated MSOs use their market power to foreclose competition.

Federal courts have split on whether to apply traditional antitrust analysis to cannabis markets. Some judges have dismissed claims on the grounds that federally illegal activity can't form the basis of antitrust injury, while others have ruled that state-legal economic activity falls within the scope of the Sherman Act regardless of federal scheduling.

Timeline and Next Steps in Legal Process

Jushi has 30 days to file its opposition to the summary judgment motion. Oral arguments are expected in late October 2026. If the court grants summary judgment, it would mark one of the first antitrust victories for an independent cannabis retailer against a major MSO without proceeding to a jury trial.

Trade associations including the National Cannabis Industry Association and the American Antitrust Institute are watching closely—both have filed amicus briefs in similar litigation. A ruling for the plaintiff could set a precedent that reshapes vertical integration strategies across limited-license states.

For full background on this story, see the CannIntel topic hub on the Jushi antitrust lawsuit.